PE20140610A1 - Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina - Google Patents
Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelinaInfo
- Publication number
- PE20140610A1 PE20140610A1 PE2013002562A PE2013002562A PE20140610A1 PE 20140610 A1 PE20140610 A1 PE 20140610A1 PE 2013002562 A PE2013002562 A PE 2013002562A PE 2013002562 A PE2013002562 A PE 2013002562A PE 20140610 A1 PE20140610 A1 PE 20140610A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- oxo
- phenyl
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINA 3-ESPIROCICLICA DE FORMULA (I) DONDE X1 ES (CRx1H)n, NRx1 O N, EN DONDE Rx1 ES H O ALQUILO(C1-C6); n ES 0 O 1; X2 ES CH, N O C; m ES 1 O 2; p ES 0 O 1; Y ES NR1 U O, EN DONDE R1 ES H, ALQUILO(C1-C6), HALOALQUILO(C1-C6), CICLOALQUILO(C3-C6), ENTRE OTROS; R2a ES -A-FENILO, -A-HETEROARILO DE 5 A 6 MIEMBROS, -A-CICLOALQUILO(C5-C6), ENTRE OTROS, EN DONDE A ES UN ENLACE, ENTRE OTROS; R2b ES H O ALQUILO(C1-C4); R3 Y R4 SON CADA UNO H, ALQUILO(C1-C6), CICLOALQUILO(C3-C6), ENTRE OTROS; R6 Y R7 SON CADA UNO H, ALQUILO(C1-C6), HIDROXIALQUILO(C1-C6) O HALOALQUILO(C1-C6); R5 ES FENILO, HETEROARILO DE 5 A 6 MIEMBROS; CICLOALQUILO(C3-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-AMINO-N-[(R)-1-BENCILOXIMETIL-2-(2-METIL-1-OXO-4-FENIL-2,7-DIAZA-ESPIRO[4.5]DEC-7-IL)-2-OXO-ETIL]-2-METIL-PROPIONAMIDA; 2-AMINO-N-((2R)-3-(BENCILOXI)-1-(4-(4-FLUOROFENIL)-2-METIL-1-OXO-2,7-DIAZAESPIRO[4.5]DECAN-7-IL)-1-OXOPROPAN-2-IL)-2-METILPROPANAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DE RECEPTORES DE LA GHRELINA SIENDO UTILES EN EL TRATAMIENTO DE GASTROPARESIA, DISPEPSIA FUNCIONAL, SINDROME DEL INTESTINO CORTO
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490848P | 2011-05-27 | 2011-05-27 | |
US201161560960P | 2011-11-17 | 2011-11-17 | |
US201261642116P | 2012-05-03 | 2012-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20140610A1 true PE20140610A1 (es) | 2014-05-31 |
Family
ID=46317469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013002562A PE20140610A1 (es) | 2011-05-27 | 2012-05-25 | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
Country Status (21)
Country | Link |
---|---|
US (2) | US8546416B2 (es) |
EP (1) | EP2714690A1 (es) |
JP (1) | JP2014515369A (es) |
KR (1) | KR20140023399A (es) |
CN (1) | CN103562206A (es) |
AP (1) | AP2013007234A0 (es) |
AR (1) | AR086554A1 (es) |
AU (1) | AU2012264305A1 (es) |
BR (1) | BR112013030391A2 (es) |
CA (1) | CA2835916A1 (es) |
CL (1) | CL2013003211A1 (es) |
CO (1) | CO6811856A2 (es) |
CR (1) | CR20130625A (es) |
EA (1) | EA201391797A1 (es) |
IL (1) | IL229320A0 (es) |
MX (1) | MX355072B (es) |
PE (1) | PE20140610A1 (es) |
SG (1) | SG194616A1 (es) |
TW (1) | TW201302749A (es) |
UY (1) | UY34094A (es) |
WO (1) | WO2012164473A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013255458A1 (en) * | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
WO2014026013A2 (en) | 2012-08-09 | 2014-02-13 | Dynamis Therapeutics, Inc. | Methods for maintaining or improving health, well-being and/or a physiological function in a subject |
MD20160116A2 (ro) | 2014-04-04 | 2017-04-30 | X-Rx Discovery, Inc | Inhibitori spirociclici substituiţi ai autotaxinei |
JP2017532350A (ja) * | 2014-10-31 | 2017-11-02 | ラクオリア創薬株式会社 | グレリン受容体アゴニストとしてのテトラヒドロピラゾロピリジン誘導体 |
JP2020519639A (ja) * | 2017-05-12 | 2020-07-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | トリアザスピロ[4.5]デカノンによる胃不全麻痺の処置 |
CN111175387B (zh) * | 2018-11-13 | 2022-06-07 | 成都康弘药业集团股份有限公司 | 一种米那普仑异构体的检测方法 |
CN113125583B (zh) * | 2019-12-30 | 2022-06-21 | 成都百裕制药股份有限公司 | 一种注射用泮托拉唑钠中基因毒性杂质含量的检测方法 |
US20230174531A1 (en) * | 2021-12-08 | 2023-06-08 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578593A (en) | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
SK282166B6 (sk) * | 1992-12-11 | 2001-11-06 | Merck & Co., Inc. | Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom |
EP0828754B1 (en) | 1995-05-29 | 2005-02-02 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
WO1997011697A1 (en) * | 1995-09-26 | 1997-04-03 | Merck & Co., Inc. | 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone |
WO1997044042A1 (en) | 1996-05-22 | 1997-11-27 | Arch Development Corporation | Sleep quality improvement using a growth hormone secretagogue |
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
AU7445498A (en) * | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
US6329342B1 (en) | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
GB9802251D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
ID29095A (id) | 1998-10-02 | 2001-07-26 | Novartis Ag Cs | Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan |
US6194578B1 (en) | 1998-11-20 | 2001-02-27 | Pfizer Inc. | Dipeptide derivatives |
SI1004583T1 (en) | 1998-11-23 | 2004-12-31 | Pfizer Products Inc. | Process and hydantoin intermediates for the synthesis of growth hormone secretagogues |
GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
DOP2001000154A (es) | 2000-05-25 | 2002-05-15 | Pfizer Prod Inc | Combinación de secretagogos de hormona del crecimiento y antidepresivos |
ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
IL143690A0 (en) | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
KR20030083755A (ko) | 2001-03-26 | 2003-10-30 | 노파르티스 아게 | 동통 치료를 위한 바닐로이드 수용체 길항제로서의 용도를위한 융합 피리딘 유도체 |
DE60235536D1 (de) | 2001-05-14 | 2010-04-15 | Novartis Ag | Sulfonamidderivate |
JP3894035B2 (ja) | 2001-07-04 | 2007-03-14 | 東レ株式会社 | 炭素繊維強化基材、それからなるプリフォームおよび複合材料 |
TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
WO2003087036A1 (en) | 2002-04-10 | 2003-10-23 | Eli Lilly And Company | Stereoselective process for the synthesis of (d)-2-amino-5-phenylpentanoic or alkyl ester thereof |
US6696468B2 (en) | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
SE0201940D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New combination II |
DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
PE20040844A1 (es) | 2002-11-26 | 2004-12-30 | Novartis Ag | Acidos fenilaceticos y derivados como inhibidores de la cox-2 |
GB0302876D0 (en) | 2003-02-07 | 2003-03-12 | Novartis Ag | Organic compounds |
JP2004277319A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1−(4−ピペリジニルメチル)ピペリジニルアミド誘導体およびそれを含有する医薬組成物 |
JP2004277318A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1−(1−置換カルボニル−4−ピペリジニルメチル)ピペリジン誘導体およびそれを含有する医薬組成物 |
CA2525502C (en) | 2003-05-21 | 2012-12-18 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
EP1505064A1 (en) | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
CN100398524C (zh) | 2003-08-12 | 2008-07-02 | 弗·哈夫曼-拉罗切有限公司 | 作为crf拮抗剂的四氢喹唑啉衍生物 |
JP2007501822A (ja) | 2003-08-12 | 2007-02-01 | エフ.ホフマン−ラ ロシュ アーゲー | コルチコトロピン放出性因子(crf)アンタゴニストとしてのスピロ置換テトラヒドロキナゾリン |
EP1664010A1 (en) | 2003-08-29 | 2006-06-07 | Vernalis (R&D) Limited | Sulfonamides antagonising n-type calcium channels |
WO2005028480A2 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
GEP20084527B (en) | 2003-09-03 | 2008-11-10 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
JP2005082508A (ja) | 2003-09-05 | 2005-03-31 | Dainippon Pharmaceut Co Ltd | 2−アルコキシ−6−アミノ−5−ハロゲノ−n−(1−置換−4−ピペリジニル)ピリジン−3−カルボキサミド誘導体およびそれを含有する医薬組成物 |
CN1878773A (zh) | 2003-09-05 | 2006-12-13 | 神经能质公司 | 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶 |
US20070027156A1 (en) | 2003-09-09 | 2007-02-01 | Hisao Nakai | Crf antagonists and heterobicyclic compounds |
GB0322612D0 (en) | 2003-09-26 | 2003-10-29 | Novartis Ag | Organic compounds |
EP1673348B1 (en) | 2003-09-30 | 2009-04-01 | Janssen Pharmaceutica N.V. | Benzoimidazole compounds |
JP2005104896A (ja) | 2003-09-30 | 2005-04-21 | Dainippon Pharmaceut Co Ltd | 2−アルコキシ−6−アミノ−5−ハロゲノピリジン−3−カルボキサミド誘導体およびそれを含有する医薬組成物 |
JP2007507514A (ja) | 2003-09-30 | 2007-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キノキサリン化合物 |
US7714009B2 (en) | 2003-10-31 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
US20090074890A1 (en) | 2003-11-10 | 2009-03-19 | Park Min K | Substituted Triazoles as Sodium Channel Blockers |
US7208596B2 (en) | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
WO2005054239A1 (en) | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
US7211568B2 (en) | 2003-12-18 | 2007-05-01 | Kosan Biosciences Incorporated | 9-Desoxoerythromycin compounds as prokinetic agents |
JP2005206590A (ja) | 2003-12-25 | 2005-08-04 | Mitsubishi Pharma Corp | ナトリウムチャネルサイト2選択的阻害剤 |
MXPA06007853A (es) | 2004-01-07 | 2007-01-26 | Aryx Therapeutics | Compuestos estereoisomericos y metodos para el tratamiento de desordenes gastrointestinales y del sistema nervioso central. |
ATE388146T1 (de) | 2004-01-29 | 2008-03-15 | Pfizer | 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor |
TW200533348A (en) | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
EP1574478A1 (de) | 2004-03-08 | 2005-09-14 | Solvay Fluor GmbH | Herstellung von Carbonylfluorid |
CN101022728B (zh) | 2004-03-25 | 2012-08-08 | 詹森药业有限公司 | 咪唑化合物 |
US20080280873A1 (en) | 2004-03-29 | 2008-11-13 | Jun Liang | Biaryl Substituted Pyrazinones as Sodium Channel Blockers |
TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
US20080015196A1 (en) | 2004-04-16 | 2008-01-17 | Neurogen Corporation | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands |
GB0412768D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
MXPA06014486A (es) | 2004-06-15 | 2007-03-01 | Pfizer | Derivados de acido carboxilico de bencimidazolona. |
SE0401653D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
WO2006023757A2 (en) | 2004-08-19 | 2006-03-02 | University Of Virginia Patent Foundation | Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents |
GB0420424D0 (en) | 2004-09-14 | 2004-10-20 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
US7396933B2 (en) | 2004-11-05 | 2008-07-08 | Theravance, Inc. | Quinolinone-carboxamide compounds |
EP1807422B1 (en) | 2004-11-05 | 2009-09-02 | Theravance, Inc. | 5-ht4 receptor agonist compounds |
US20080269239A1 (en) | 2004-11-11 | 2008-10-30 | Argenta Discovery Ltd. | Pyrimidine Compounds as Histamine Modulators |
US20060111416A1 (en) | 2004-11-24 | 2006-05-25 | Lane Charlotte A L | Octahydropyrrolo[3,4-C]pyrrole derivatives |
ATE469897T1 (de) | 2004-12-22 | 2010-06-15 | Theravance Inc | Indazolcarbonsäureamidverbindungen |
EP1818061A1 (en) | 2005-12-02 | 2007-08-15 | Charite-Universitätsmedizin Berlin | Use of ghrelin for stimulating hair growth |
US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
JP2010518090A (ja) | 2007-02-09 | 2010-05-27 | トランザイム・ファーマ,インコーポレイテッド | 大環状グレリン受容体修飾因子およびその使用方法 |
US7994203B2 (en) | 2008-08-06 | 2011-08-09 | Novartis Ag | Organic compounds |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
BR112012007183A2 (pt) | 2009-09-30 | 2017-06-20 | Tranzyme Pharma Inc | solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kit |
-
2012
- 2012-05-24 US US13/479,596 patent/US8546416B2/en active Active
- 2012-05-24 UY UY0001034094A patent/UY34094A/es not_active Application Discontinuation
- 2012-05-24 AR ARP120101842A patent/AR086554A1/es unknown
- 2012-05-25 WO PCT/IB2012/052649 patent/WO2012164473A1/en active Application Filing
- 2012-05-25 TW TW101118859A patent/TW201302749A/zh unknown
- 2012-05-25 AU AU2012264305A patent/AU2012264305A1/en not_active Abandoned
- 2012-05-25 EA EA201391797A patent/EA201391797A1/ru unknown
- 2012-05-25 SG SG2013079082A patent/SG194616A1/en unknown
- 2012-05-25 AP AP2013007234A patent/AP2013007234A0/xx unknown
- 2012-05-25 CA CA2835916A patent/CA2835916A1/en not_active Abandoned
- 2012-05-25 PE PE2013002562A patent/PE20140610A1/es not_active Application Discontinuation
- 2012-05-25 CN CN201280025862.9A patent/CN103562206A/zh active Pending
- 2012-05-25 KR KR1020137034118A patent/KR20140023399A/ko not_active Application Discontinuation
- 2012-05-25 JP JP2014512000A patent/JP2014515369A/ja active Pending
- 2012-05-25 EP EP12727947.9A patent/EP2714690A1/en not_active Withdrawn
- 2012-05-25 BR BR112013030391A patent/BR112013030391A2/pt not_active Application Discontinuation
- 2012-05-25 MX MX2013013950A patent/MX355072B/es active IP Right Grant
-
2013
- 2013-08-08 US US13/962,689 patent/US20130331369A1/en not_active Abandoned
- 2013-11-07 IL IL229320A patent/IL229320A0/en unknown
- 2013-11-08 CL CL2013003211A patent/CL2013003211A1/es unknown
- 2013-11-20 CO CO13273132A patent/CO6811856A2/es active IP Right Grant
- 2013-11-27 CR CR20130625A patent/CR20130625A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2012264305A1 (en) | 2013-11-21 |
MX355072B (es) | 2018-04-04 |
TW201302749A (zh) | 2013-01-16 |
AR086554A1 (es) | 2014-01-08 |
IL229320A0 (en) | 2014-01-30 |
US20120302540A1 (en) | 2012-11-29 |
CN103562206A (zh) | 2014-02-05 |
AP2013007234A0 (en) | 2013-11-30 |
CL2013003211A1 (es) | 2014-07-04 |
KR20140023399A (ko) | 2014-02-26 |
SG194616A1 (en) | 2013-12-30 |
JP2014515369A (ja) | 2014-06-30 |
US8546416B2 (en) | 2013-10-01 |
CO6811856A2 (es) | 2013-12-16 |
CR20130625A (es) | 2014-02-04 |
WO2012164473A1 (en) | 2012-12-06 |
EA201391797A1 (ru) | 2014-04-30 |
UY34094A (es) | 2013-01-03 |
BR112013030391A2 (pt) | 2016-12-13 |
CA2835916A1 (en) | 2012-12-06 |
MX2013013950A (es) | 2014-01-23 |
EP2714690A1 (en) | 2014-04-09 |
US20130331369A1 (en) | 2013-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20140610A1 (es) | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina | |
PE20090773A1 (es) | Derivados de morfolina pirimidina | |
PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
NO341631B1 (no) | Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger | |
PE20080890A1 (es) | DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
PE20090641A1 (es) | Amidas heterociclicas | |
NO20083582L (no) | Pyridin-2-karboksamide derivater | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
PE20091573A1 (es) | Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa | |
PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
MX2007007428A (es) | Compuestos heterociclicos, antagonistas de ccr2b. | |
AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
PE20090620A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
PE20090482A1 (es) | Derivados heterociclicos como antagonistas del receptor ccr2 | |
NO20076424L (no) | N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser | |
PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |